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Introduction
DiabeticRetinopathy (DR) is a frequent complicationofDiabetesMellitus (DM)and themain causeof
vision loss in the working population in western countries. Diabetic Retinopathy has always been con-
sidered a microvascular disease, but it has been suggested that neurodegeneration is also associated with
this complex pathology[1], although there is evidence indicating that the neurodegenerative process may
progress independently[2]. To evaluate this potential association, we have examined the progression of
neurodegeneration over a 5-year period of follow-up (considering thinning of ganglion cell + inner plexi-
form retinal layers (GCL+IPL) in individuals with type 2 diabetes (T2D) and nonproliferative DR) and
exploredwhether it is associatedwithmicroaneurysm turnover (MAT), disease level at baseline and sever-
ity progression.
Methods
This study was designed as a 5-year prospective, longitudinal study (ClinicalTrials.gov identifier:
NCT03010397), to evaluate disease progression inT2D individuals.
212 T2D individuals with mild non-proliferative diabetic retinopathy (NPDR, ETDRS (Early Treat-
ment Diabetic Retinopathy Study) level 20 or 35)[3] were included in the study, of which 145 completed
the 5-year follow-up, with ophthalmological examinations performed at baseline and annually (one eye
per patient). GCL+IPLaverage thicknesswas evaluated by optical coherence tomography (OCT). Classi-
fication in ETDRS levels assesses severity of DR and was performed by grading of 7-fields color fundus
photography. Severity progression was determined as step changes between levels of ETDRS at baseline
and at the 5-year follow-up and was classified as improvement/maintenance or worsening. Microan-
eurysm turnover (MAT) was evaluated using the RetMarkerDR considering a cut-off of 6, identified
previously to characterizemicrovascular disease activity [4].
Linearmixed-effectsmodelswitha randomintercept for thepatientwereused toassess theprogression
ofGCL+IPLthicknessover time (6annualvisits), adjusting for ageandgender.Separatemodelswereused
to analyse the effect of ETDRS severity progression, ETDRS at baseline, MAT≥6 and the interaction of
these parameters with time on GCL+IPL thickness. Statistical analysis was performed with Stata 16.1
(StataCorp. 2019. Stata Statistical Software: Release 16. College Station,TX: StataCorpLLC.StataCorp.
LP,CollegeStation,TX,USA), and aP-value ≤0.05was considered statistically significant.
Results
The analysis included 144 subjects, as one individual was excluded due to inconsistencies in the auto-
matically collectedOCTdata.
The effect estimates of time, adjusted for age and gender, onGCL+IPLaverage thickness are reported
in table 1 and expected progression of GCL+IPL thickness over the 6 visits is depicted in figure 1.
GCL+IPL thickness showed an estimated decrease of 1.40µmover the 5-year period in relation to the first
visit,whenothervariables remainconstant, adjusted forage (p-value:<0.001)andgender (p-value:0.015).
When evaluating the effect of the variables of interest, by adding them to the model, the effect of
ETDRS step change was not statistically significant (p-value: 0.332), but the interaction of ETDRS level
progressionwith time showed a significant effect onGCL+IPLaverage thickness (p-value: 0.008) (figure
2). Noteworthy, the effect of time on ETDRS step change groups was significant on those individuals
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where DR severity was maintained or improved (p-value: <0.001), and not in those that showed ETDRS
severity worsening (p-value: 0.079), suggesting that GCL+IPLdecrease does not appear to be associated
withDRseverity progression.
Finally, themodels that consideredETDRS level at baseline andMATdidnot showsignificant effect of
theseparameters (p-value: 0.821andp-value: 0.682, respectively) and their interactionwith time (p-value:
0.971andp-value:0.992, respectively)onGCL+IPLaverage thickness (figure3,SupplementaryMaterial).
Discussion and Conclusions
Through these analyses,we have demonstrated that in a 5-year period of follow-up there is progressive
thinning ofGCL+IPL, indicating that progressive neurodegeneration occurs inNPDR.However, no clear
association was identified with microvascular disease (represented by MAT), disease level and severity
progression of the retinal disease. Future studies should further explore the association of severity
improvement andmaintenancewith neurodegenerative changes.
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Table 1 - Fixed effects ß coefficients (µm), 95% Confidence Interval (CI) and p-value of age, gender, and time on
GCL+IPL Average thickness obtained from linear mixed effects model with a random intercept for patient.
Fixed Effects ß 95% CI p-value
Lower Upper
Age -0.30 -0.46 -0.14 <0.001
Gender
Female 3.07 0.60 5.54 0.015
Time
Visit 2 -0.75 -1.10 -0.41 <0.001
Visit 3 -0.59 -0.94 -0.25 0.001
Visit 4 -0.82 -1.17 -0.47 <0.001
Visit 5 -1.29 -1.64 -0.95 <0.001
Visit 6 -1.40 -1.74 -1.06 <0.001
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ETDRS imp/maint ETDRS worse
Expected of GCL+IPL thickness over 5 years period by ETDRS step change
Figure 1 - Expected progression of GCL+IPL thickness
over 5 years period by ETDRS step change: predictive
margins of the interaction of time with ETDRS step
change, with 95% CI (p-value of the interaction: 0.008)
Figure 2 - Expect progression of GCL+IPL thickness (µm)
over 5-year follow-up: predictive margins of time with 95%
CI, adjusted for age and gender obtained from linear mixed
effects model with a random intercept for the patient.
